[Cytochromes P-450, drug disease, and personified medicine. Part I].
The review summarizes data on the molecular basis of medication metabolism, factors forming the personal profile of cytochrome P-450, methods to estimate the activity of the monooxygenase system, and problems of medication interference and therapeutic pharmacomonitoring, forming the basis of personified medicine. Special attention is paid to the cytochrome-P-450-containing hepatic system, responsible for inter-individual differences after administration of medications in therapeutic doses. Factors influencing the condition of the monooxygenase system: cytochrome P-450 genetic polymorphism, inducing of inhibition of these systems by medications, and crisscross substrate specificity of cytochrome P-450 are considered. Different methodical approaches (genomic and proteomic ones, bioelectrochemical nanotechnologies, and therapeutic pharmacomonitoring) to obtaining full information on cytochrome P-450 for each individual are compared. The article substantiates the necessity to assess individual features of the monooxygenase system to optimize medication therapy.
Archakov
A I
AI
Lisitsa
A V
AV
Petushkova
N A
NA
Karuzina
I I
II
D001711:Biotransformation / Q000502:physiology*; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism*; D004347:Drug Interactions / Q000502:physiology*; D016903:Drug Monitoring / Q000379:methods*; D006801:Humans; D015262:Xenobiotics / Q000493:pharmacokinetics
D015262:Xenobiotics; D003577:Cytochrome P-450 Enzyme System